| Description | Teniloxazine is an orally available antidepressant compound with anti-hypoxic properties. |
| In vivo | Teniloxazine（80毫克；口服；每日两次；7天；12名健康志愿者及12名肝硬化患者）。在健康志愿者中，观察到口服清除率CLo的增加，从平均值（标准差）14.6（3.9）增至18.0（6.6）ml min^-1 kg^-1。而在肝硬化患者中，Teniloxazine的药代动力学参数基本保持不变。与正常受试者相比，肝硬化患者的CLo大约减半，而t 1/2则增加一倍多。[1] |
| Target activity | 5-HT2A receptor:49 nM(Ki) |
| molecular weight | 289.39 |
| Molecular formula | C16H19NO2S |
| CAS | 62473-79-4 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Orlando R, et al. The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis. Br J Clin Pharmacol. 1995;39(4):445-448. 2. Kinoshita T. Quantitative pharmaco-EEG study of nootropics. Seishin Shinkeigaku Zasshi. 1990;92(5):255-276. 3. Makoto Kuriyama. Therapeutic agent for attention-deficit hyperactivity disorder. US20090048243A1. |